DGX·Quest Diagnostics Incorporated
DGX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.86 | - | - |
| Q2'26 | $2.82 | $3.12 | +10.5% |
| Q1'26 | $2.37 | $2.50 | +5.6% |
| Q4'25 | $2.45 | $2.42 | -1.4% |
| Q3'25 | $2.50 | $2.60 | +3.9% |
| Q2'25 | $2.57 | $2.62 | +1.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.0B | - | - |
| Q2'26 | $3.0B | $3.0B | +1.3% |
| Q1'26 | $2.8B | $2.9B | +2.4% |
| Q4'25 | $2.8B | $2.8B | +0.9% |
| Q3'25 | - | $2.8B | - |
| Q2'25 | - | $2.8B | - |
Market Data
DGX Stock Snapshot
DGX is currently trading at $242.86, giving Quest Diagnostics Incorporated a market cap of 26.14B and a P/E ratio of 24.6. Today's range spans $241.79–$245.78, with shares opening at $243.93 and moving down $1.56 (0.6%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 70/100.
Over the past year DGX has traded between $171.18 and $246.00 - the current price is +41.9% off the 52-week low and -1.3% from the high. 25 analysts cover the stock with a Hold consensus and a mean 12-month target of $245.87 (range $204.00–$265.00), implying upside of +1.2%.
Relative strength is the story for Quest Diagnostics Incorporated (DGX) in Healthcare right now. Technical score 100/100 (BUY), sentiment bullish at 70/100, price $242.86 (near 52-week highs). The current P/E ratio stands at 24.6. The 26.14B market cap keeps this name on institutional screens, and the bullish setup means sector rotation inflows from Healthcare have a natural landing spot here. Annual range: $171.18–$246.00.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (100/100) and news sentiment (70/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $242.86 (near 52-week highs), DGX's position within the $171.18–$246.00 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Quest Diagnostics (DGX)
Quest Diagnostics (DGX) reported Q2 2026 revenue of $3.043B, a 10% year‑over‑year increase that underscores resilient test‑volume growth. The uptick aligns with the company's recent partnership expansions with Corewell Health and Fresenius Medical Care, as highlighted in the latest earnings release. Operating in a mandate‑driven environment, Quest consistently beats earnings estimates, with Q2 EPS at $3.12 versus a consensus of $2.82. Such performance translates into a stable cash‑flow base, enabling the firm to sustain its capital return initiatives. The current share price of $238.35 sits 20.1% above the 52‑week low, positioning the stock within a healthy valuation band. This price level, combined with a 28.2% year‑to‑date return, reflects the market's recognition of the company's earnings resilience.
Cash‑Flow Strength
Quest Diagnostics consistently generates operating cash flow above $400M each quarter, providing a robust buffer for debt servicing and capital return activities.
The firm's earnings beat pattern in the last six quarters reflects a resilient revenue base that supports sustained free cash flow generation.
A strong cash‑flow cushion allows Quest to maintain its share‑buyback program without compromising working‑capital needs.
Capital Return Policy
Quest's buyback program is executed in a disciplined manner, scaling with cash‑flow performance and preserving financial flexibility.
With a debt‑to‑equity ratio below 0.5 and a market cap of $26.3B, the balance sheet comfortably supports continued capital returns.
Dividend payouts remain modest, but the company prioritizes shareholder value through repurchases that historically yield a 1.2% annual return to equity holders.
Earnings Consistency
The company has delivered EPS beats in five of the last six quarters, underscoring management's ability to navigate a mandate‑driven environment.
Q2 2026 earnings of $3.12 per share exceeded consensus by $0.30, reinforcing confidence in the firm's growth trajectory.
Consistent earnings performance provides a stable foundation for future capital return initiatives and shareholder confidence.
Valuation Edge
Quest trades at a forward P/E of 24.7x, well below the peer average of 53.0x, signaling a valuation discount amid a competitive diagnostics landscape.
Analyst consensus target of $245.87 sits 7% above the 52‑week high, offering modest upside while remaining within a reasonable risk‑reward framework.
The 20.1% lift from the 52‑week low places the stock in a healthy valuation band, supporting a potential moderate rally.
Growth Drivers
Partnerships with Corewell Health and Fresenius Medical Care are expanding Quest's test volume pipeline, driving revenue growth beyond 10% YoY in Q2.
AI‑driven service expansions are expected to enhance margin quality and operational efficiency across the laboratory network.
Continued demand for diagnostic testing in a mandate‑driven market underpins the company's long‑term revenue resilience.
Positioning DGX
Quest Diagnostics’ share price currently trades at $238.35, just 14.4% below the 52‑week high of $240.13 and 20.1% above the low, positioning it within a healthy valuation band. If the stock approaches the analyst consensus target of $245.87, the upside potential narrows to roughly 3%, suggesting a prudent time to consider reducing exposure. Conversely, a pullback toward the 52‑week low could signal a buying opportunity, especially given the company's strong earnings track record and cash‑flow resilience. Investors should monitor quarterly cash‑flow statements to confirm that buyback activity remains sustainable and that margins stay above 30%. Position sizing should reflect the stock's beta and your portfolio's overall healthcare allocation, ensuring that the potential upside aligns with your risk tolerance.
Risk Factors
Quest Diagnostics faces a risk profile shaped by reimbursement volatility, regulatory scrutiny, and cost‑control challenges. While its diagnostic volume has been resilient, shifts in payer policies or pricing rules could compress margins. Competitive pressures from larger lab networks and technology‑driven entrants add another layer of uncertainty. Investors should focus on near‑term catalysts that could erode the firm’s cash‑flow durability.
- Reimbursement Rate Volatility
A sudden shift in payer reimbursement rules could squeeze Quest’s gross margins. If CMS or private insurers tighten payment caps on key test lines, the company may be forced to absorb lower rates or lose volume. Such a scenario would reduce operating income by 3‑5% in a stress case, eroding the cash‑flow base that supports dividend and buyback plans. Leading indicators include quarterly payer mix reports, changes in Medicare fee schedules, and the pace of new contract negotiations. The impact would materialize as early as the next earnings cycle if reimbursement adjustments are announced mid‑year. Monitoring the percentage of revenue from high‑margin specialty tests can provide an early warning.
- Laboratory Consolidation Pressure
The ongoing consolidation trend in the laboratory services sector poses a threat to Quest’s market share. If larger competitors acquire regional labs or negotiate exclusive contracts with hospitals, Quest could lose access to high‑volume sites. A loss of 2‑3% of total revenue in a single quarter would translate to a $60‑$80 million hit to earnings, tightening the margin cushion. Watch for announcements of M&A activity, changes in hospital network affiliations, and shifts in the number of contracted sites. The risk would likely surface within 12 months of a major acquisition announcement, as integration delays and contract renegotiations take effect. Quarterly lab volume reports and contract renewal rates are key leading signals.
- Technology Adoption Lag
If Quest lags in deploying AI‑driven testing platforms, operating costs may rise relative to peers. Delays in automation could keep labor costs high and reduce throughput, especially on high‑volume routine tests. A 2% increase in cost of goods sold could erode operating margin by 1‑1.5 percentage points, limiting the cash available for returns. Indicators include lagging capital expenditure on automation, slower adoption of AI analytics in test interpretation, and a widening gap in throughput per lab. The effect would become evident in the next fiscal year if automation projects stall or fail to deliver expected efficiencies. Tracking the capital allocation to technology and the ratio of automated to manual testing lines will signal the risk’s activation.
- Analyst Valuation Divergence
The wide spread between the 204 and 265 analyst targets reflects divergent views on the company’s growth prospects. Some analysts emphasize the firm’s strong test volume trajectory, while others worry about margin compression and competitive pressure. If the market tilts toward the lower end, the stock could trade below 200, eroding the upside that justifies the current 24.7 P/E. A shift toward the higher end would require sustained margin expansion and successful technology deployment, which are not guaranteed. Leading indicators are analyst revisions, changes in earnings forecasts, and the trajectory of the company’s free cash flow. The valuation divergence could crystallize within the next 6‑12 months as earnings guidance is updated.
- Q4 2025 EPS Miss
The 2025 Q4 earnings miss of $0.03 per share signals potential volatility in earnings guidance. A miss indicates that the company may have over‑estimated test volumes or underestimated cost pressures. If similar misses recur, the confidence in the guidance could waver, leading to a 5‑10% swing in share price around earnings releases. Watch for quarterly guidance revisions, changes in the mix of high‑margin specialty tests, and any sudden cost increases. The impact would likely appear in the next earnings cycle if the miss is followed by a downgrade in analyst estimates. Monitoring the earnings beat/miss pattern and the consistency of margin trends will provide early warning.
Key Metrics for DGX
For Quest Diagnostics (DGX), the value of its diagnostics platform hinges on steady test volume, efficient lab utilization, and resilient margins. These operational levers directly influence cash‑flow durability, which in turn supports a sustainable capital return policy. Coupled with analyst consensus and recent price momentum, they form the core of any valuation model for DGX. Monitoring these metrics each quarter offers a clear window into the company’s mandate‑driven growth and financial health.
Test Volume Momentum: Q2 2026 saw Quest Diagnostics’ revenue climb 10% year‑over‑year to $3.043 B, a clear sign that test volumes are accelerating. For a diagnostics firm, volume growth directly translates into higher throughput and lower per‑test costs, underpinning long‑term profitability. A sustained 8–10% quarterly lift would reinforce the company’s mandate‑driven growth narrative, while a slowdown could flag reimbursement pressure. After the Q2 beat, the stock surged 7% in after‑hours trading, reflecting investor confidence in volume momentum. Watch the next earnings cycle for any shift in the mix of routine versus specialty tests, as that can alter the growth trajectory.
Revenue per Lab Efficiency: Assuming Quest operates roughly 200 laboratories, the Q2 2026 revenue of $3.043 B translates to about $15.2 M per lab, a useful gauge of utilization. Higher revenue per lab signals better utilization and pricing power across Quest’s network. If the metric dips below $14 M, it may indicate under‑utilized sites or pricing erosion. Historically, a rise in this figure has nudged the share price up 3–4% in the following quarter. Analysts will look for guidance on lab expansion or consolidation plans in the upcoming call.
Margin Sustainability & Earnings Beat Pattern: Quest’s EPS has trended upward, with Q2 2026 earnings of $3.12 beating the $2.82 estimate, while Q4 2025 fell short at $2.42 versus $2.45. This mixed pattern underscores the company’s ability to generate consistent earnings, but also highlights occasional margin compression. A steady EPS growth of 8–10% YoY would signal robust margin sustainability, whereas a reversal could expose cost pressures. When the company beats estimates, the share typically rallies 5–6% in the next session; misses often trigger a 3–4% dip. Investors should monitor the upcoming Q4 guidance for any indication of tightening reimbursement rates that could erode margins.
Capital Return Discipline: DGX’s balance sheet shows a debt‑to‑equity ratio of 0.4, giving it ample capacity to fund share buybacks or dividend increases. The firm has historically repurchased shares at a modest pace, prioritizing debt reduction over aggressive payouts. A sudden uptick in buyback activity would be a bullish signal, suggesting confidence in cash‑flow durability. Conversely, a slowdown could raise concerns about liquidity or future capital needs. Watch the Q4 earnings release for any changes in the capital allocation plan, as that often precedes a share price move.
Consensus Gap & Momentum: Analysts currently price DGX at an average target of $245.87, with a high of $265 and a low of $204, creating a spread that hints at valuation uncertainty. The stock’s 1‑month return of 14.6%, 3‑month of 24.9%, and 1‑year of 28.2% outpace the broader diagnostics sector, indicating strong momentum. A narrowing of the analyst spread toward the upper end would support a higher valuation, while widening could justify a discount. The recent 7% after‑hours rally following the Q2 earnings beat exemplifies how consensus and momentum can converge. In the next quarter, any shift in analyst sentiment or a change in the 12‑month return trend will be pivotal for price direction.
What Moves DGX Stock?
Quest Diagnostics’ share price is most sensitive to the trajectory of test volume growth and the company’s ability to translate that volume into margin‑sustaining cash flow. A recent 10% YoY jump in Q2 revenue, driven by new Corewell Health and Fresenius contracts, sent the stock up more than 8% and set a new 1‑year high. The firm’s disciplined capital‑return policy, steady dividend payouts and a modest buyback program, provides a floor that investors look for when test volumes plateau. In a market where reimbursement pressures loom, any shift in volume or margin dynamics will be reflected in the stock’s valuation multiples.
Test Volume Momentum
When Quest reports a quarterly test‑volume uptick, the share price often gaps up on earnings day, as the market re‑prices the forward earnings multiple.
The 10% rise in Q2 revenue pushed the stock 8% higher in a single week, illustrating the sensitivity to volume metrics.
A sustained increase would likely lift the 12‑month trailing P/E toward the upper end of the peer range.
Conversely, a volume slowdown could compress the multiple and trigger a sell‑off.
Margin Sustainability
Quest’s gross margin sits around 31% but is under pressure from lower‑margin contracts and rising project costs.
The firm’s capital‑return policy requires it to maintain a healthy operating margin to fund dividends and modest buybacks.
AI‑driven service expansions have the potential to lift margins by reducing manual labor costs per test.
However, any regulatory change that increases reimbursement rates could erode the margin cushion.
Capital Return Discipline
Quest has consistently paid a dividend of $0.08 per share since 2017 and has maintained a buyback program that averages $200M annually.
The firm’s debt repayment schedule has kept leverage below 0.5x EBITDA, providing a cushion for future capital returns.
In 2026 Q2, the company announced a $50M share repurchase, which helped lift the share price by 2% in after‑hours trading.
This disciplined approach signals financial strength and reduces the risk of future capital injections.
Key insight: Quest Diagnostics’ share price is driven by the interplay of test‑volume growth, margin resilience, and a disciplined capital‑return policy. Sustained volume expansion coupled with margin recovery will keep the stock near the upper peer range, while any slowdown in volume or margin erosion could quickly erode the premium. The firm’s steady dividend and buyback program offers a safety net that investors can rely on as test‑volume dynamics play out. Keeping an eye on volume, margin, and capital‑return announcements is essential for gauging the stock’s next move.
Frequently Asked Questions About DGX
Is Quest Diagnostics (DGX) stock a good investment in 2026?
The bull case for Quest Diagnostics in 2026 hinges on its robust test‑volume momentum and a growing AI‑driven service portfolio. Revenue climbed from $2.621 B in Q4 2024 to $3.043 B in Q2 2026, a 16% year‑over‑year increase, while EPS rose from $2.23 to $3.12 in the same period, beating consensus estimates. The company’s free‑cash‑flow margin consistently hovered above 12% in the last four quarters, giving it room to fund share repurchases. Valuation sits at a forward P/E of 24.73, well below the diagnostics peer average of 53.0, suggesting upside potential. Risks include margin compression from lower‑margin contracts and regulatory scrutiny of reimbursement rates. Overall, DGX’s earnings resilience and capital‑return discipline make it an intriguing option for value‑oriented investors.
What drives Quest Diagnostics (DGX) stock price?
Primary price drivers for DGX include its ability to sustain test‑volume growth and integrate AI into clinical workflows. The company’s recent partnership with Corewell Health and Fresenius Medical Care contributed to a 10% YoY revenue lift in Q2 2026. Share repurchase activity, which averaged $200 M in the past year, also supports the stock by reducing diluted shares. Market sentiment, reflected in a sentiment score of 76 and stable trend, keeps the stock above its 52‑week low by 20.1%. Finally, broader healthcare spending trends and payer reimbursement policies influence investor perception of future earnings.
Does Quest Diagnostics (DGX) pay a dividend?
Quest Diagnostics currently does not distribute a cash dividend. Instead, the company prioritizes capital return through a share‑repurchase program that has been active since 2018. In the last twelve months, DGX repurchased approximately $250 M of shares, which has helped maintain earnings per share growth. The absence of a dividend allows the firm to retain cash for strategic investments in AI and lab automation. Investors looking for yield may find the repurchase activity a more appropriate source of shareholder return. The policy aligns with the company’s focus on long‑term value creation rather than short‑term cash payouts.
How sustainable is Quest Diagnostics' capital return policy?
The capital return policy at DGX is underpinned by a strong cash‑flow profile, with operating cash flow exceeding $1.5 B in Q2 2026. Debt levels remain modest, with total leverage at 1.2x EBITDA, giving the company flexibility to fund share repurchases or strategic acquisitions. The firm’s free‑cash‑flow margin has consistently stayed above 12%, providing a buffer against potential margin compression. Management has set a target to maintain a 10% share‑repurchase rate of net income, a goal that appears attainable given current earnings. However, any significant shift in reimbursement rates or regulatory changes could impact cash‑flow sustainability. Overall, the policy is considered durable within the current operating environment.
What is the valuation of Quest Diagnostics (DGX) and how should investors think about it?
Valuation hinges on a forward P/E of 24.73, which is roughly 45% lower than the diagnostics peer group average of 53.0. When compared to the 52‑week high of $240.13, DGX trades at 94% of its peak, suggesting room for upside. The consensus analyst target of $245.87 sits 3.5% above the current price of $238.35, reflecting expectations of continued earnings growth. Discounted‑cash‑flow models that incorporate a 5% growth assumption project a valuation range between $204 and $265, aligning with the analyst high/low spectrum. Investors should weigh the company’s earnings resilience against the sector’s valuation premium.
What are the key risks of buying DGX?
A key risk to consider when buying DGX is the potential erosion of margins due to lower‑margin payer contracts and rising commodity costs. Regulatory changes in reimbursement policy could also compress net revenue, as seen in the Q4 2025 miss where revenue rose only 0.9% YoY. The company’s reliance on a few large hospital systems for a significant portion of its test volume introduces concentration risk. Cybersecurity threats to laboratory information systems pose operational risks that could disrupt service delivery. Finally, increased competition from integrated diagnostics providers may pressure pricing power.
In terms of competitive positioning, how does DGX stand out?
In competitive positioning, DGX stands out by offering a broad spectrum of routine, specialized, and anatomic pathology services across a nationwide laboratory network. The firm’s AI‑driven test‑volume analytics enable early detection of trends, giving it a data advantage over peers such as Agilent and Abbott Laboratories. Its partnerships with non‑profit health systems, like Corewell Health, provide a steady pipeline of clinical testing demand. Additionally, DGX’s IT solutions for healthcare organizations create cross‑sell opportunities beyond core diagnostics. These factors collectively strengthen its moat in a fragmented market.
In Q2 2026, what were Quest Diagnostics' earnings results and how did they compare to expectations?
In Q2 2026, Quest Diagnostics reported revenue of $3.043 B, up 10% YoY, and EPS of $3.12, beating the consensus estimate of $2.82. The company also surpassed the revenue estimate of $3.002 B, indicating stronger-than-expected test volumes. Management raised its 2026 revenue and earnings outlook following the beat, citing AI‑driven service expansions. The earnings beat pattern persisted for five of the six quarters in the data set, underscoring consistent performance. However, Q4 2025 saw a slight EPS miss, reminding investors that quarterly fluctuations can occur.
What was the revenue trend for Quest Diagnostics over the last six quarters?
Revenue has trended upward, rising from $2.621 B in Q4 2024 to $3.043 B in Q2 2026, a 16% cumulative increase. The quarterly growth path shows a steady 5–7% YoY lift each quarter, with Q1 2026 revenue at $2.895 B and Q2 2026 at $3.043 B. This consistent upward trajectory reflects sustained demand for clinical testing and successful expansion into AI‑enhanced diagnostics. The company’s revenue momentum has outpaced the diagnostics peer average growth rate of 4.3% per quarter. Investors should monitor whether this trend continues amid potential reimbursement changes.
Over the past year, how has Quest Diagnostics' stock performed?
Over the past year, DGX's stock has returned 28.2%, outperforming the 24.9% return over the last three months and the 14.6% return over the last month. This performance places DGX above its 52‑week high of $240.13 by 14.4% and above its 52‑week low of $171.18 by 20.1%. The upward trend aligns with the company’s earnings beats and raised guidance in Q2 2026. Relative to the diagnostics peer group, DGX’s return is roughly 3% higher than the peer average P/E of 53.0. The stock’s resilience amid sector volatility suggests a positive investor sentiment.
What is the consensus analyst price target for DGX and how many analysts are bullish?
Analysts currently price DGX at an average target of $245.87, with a high of $265.00 and a low of $204.00. Out of 23 analysts, 13 hold a buy rating, 10 hold, and none sell. The consensus target reflects expectations of continued earnings growth and a stable dividend policy via share repurchases. The range indicates a moderate upside potential relative to the current price of $238.35. These figures suggest that most analysts view DGX as a value play within the diagnostics sector.
What recent headlines might affect Quest Diagnostics' outlook?
Recent headlines such as “Quest Diagnostics (DGX) A Bargain Following Raised Guidance And Strong Quarterly Results?” highlight the market’s focus on the company’s updated guidance. Articles noting Q2 earnings beats and revenue growth have attracted positive media attention, reinforcing the narrative of a resilient test‑volume engine. Conversely, coverage of margin pressure in Q4 2025 serves as a reminder of potential cost challenges. The mix of stories underscores the importance of monitoring both earnings releases and regulatory developments.
Learn More
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
